Rumitha Chakilam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rumitha Chakilam has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Hannan
Department of Medicine, Quaid-e-Azam Medical College, Bahawalpur, Pakistan
1 shared publication - Gayatri Brahmandam
Department of Medicine, Adichunchanagiri Institute of Medical Sciences, Mandya, India
1 shared publication - Ibrahim Khalil
Department of Medicine, Dhaka Medical College and hospital, Dhaka, Bangladesh
1 shared publication - Lina Elkadri
School of Medicine, The University of Jordan, Amman, Jordan
1 shared publication - Rithish Nimmagadda
Department of Internal Medicine, One Brooklyn Health, New York, NY 11213, USA
1 shared publication - Sajjad Ghanim Al-Badri
College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq
1 shared publication
Latest Publications
- Open Access
- 9 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8434-8442
Long-term proton pump inhibitor use and risk of dementia: a focused review on pantoprazole
Background: Proton pump inhibitors (PPIs) are widely prescribed for acid-related disorders, yet concerns about their long-term effects on cognitive function persist. Emerging evidence suggests a possible association between prolonged PPI use and increased dementia risk, though findings remain inconclusive. This narrative review focuses on pantoprazole, a PPI with unique pharmacokinetics, to assess its potential role in dementia development. Methods: A systematic search was conducted using PubMed and PubMed Central with keywords including “dementia,” “proton pump inhibitors,” “Alzheimer’s disease,” and “adverse effects of PPIs,” etc. Studies published from 1 January 2002 to 31 December 2024 were included, focusing on clinical trials, cohort studies, meta-analyses, and systematic reviews. Two independent reviewers assessed eligibility by screening abstracts and full texts, excluding case reports, conference abstracts, and editorial letters. Results: Thirteen studies investigating the association between PPI use and dementia were included. Observational studies in Asian populations reported an increased risk, whereas Western studies showed inconsistent results. Mechanistic insights suggest PPIs may contribute to dementia through amyloid-β accumulation, vitamin B12 deficiency, and endothelial dysfunction. Mendelian randomization studies and meta-analyses found no statistically significant association. Pantoprazole’s prolonged acid suppression may differentially influence dementia risk. Conclusion: Evidence on the link between long-term PPI use and dementia is conflicting, with variability in study populations and methodological limitations. Further prospective studies and randomized controlled trials are needed to clarify causality. Clinicians should exercise caution, reassess long-term PPI necessity, and consider alternatives to mitigate potential risks.
- 9 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8434-8442
Open AccessLong-term proton pump inhibitor use and risk of dementia: a focused review on pantoprazole
Background: Proton pump inhibitors (PPIs) are widely prescribed for acid-related disorders, yet concerns about their long-term effects on cognitive function persist. Emerging evidence suggests a possible association between prolonged PPI use and increased dementia risk, though findings remain inconclusive. This narrative review focuses on pantoprazole, a PPI with unique pharmacokinetics, to assess its potential role in dementia development. Methods: A systematic search was conducted using PubMed and PubMed Central with keywords including “dementia,” “proton pump inhibitors,” “Alzheimer’s disease,” and “adverse effects of PPIs,” etc. Studies published from 1 January 2002 to 31 December 2024 were included, focusing on clinical trials, cohort studies, meta-analyses, and systematic reviews. Two independent reviewers assessed eligibility by screening abstracts and full texts, excluding case reports, conference abstracts, and editorial letters. Results: Thirteen studies investigating the association between PPI use and dementia were included. Observational studies in Asian populations reported an increased risk, whereas Western studies showed inconsistent results. Mechanistic insights suggest PPIs may contribute to dementia through amyloid-β accumulation, vitamin B12 deficiency, and endothelial dysfunction. Mendelian randomization studies and meta-analyses found no statistically significant association. Pantoprazole’s prolonged acid suppression may differentially influence dementia risk. Conclusion: Evidence on the link between long-term PPI use and dementia is conflicting, with variability in study populations and methodological limitations. Further prospective studies and randomized controlled trials are needed to clarify causality. Clinicians should exercise caution, reassess long-term PPI necessity, and consider alternatives to mitigate potential risks.